-
Product Insights
Parkinson's Disease - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Parkinson's Disease - Global Clinical Trials Review, 2026" provides an overview of Parkinson's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Parkinson's Disease in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. Across the 68 markets, sales in the Parkinson's Disease market were $5.1 billion in 2023, growing to $10.1 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 66.0% and 69.6% of 68-market sales in 2023 and 2033, respectively.
-
Sector Analysis
Parkinson's Disease Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimated that the PD market was $3.4 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.0 billion, increasing at a compound annual growth rate (CAGR) of 7.6%. The major drivers of growth in the PD market will be the launch of several pipeline products including novel...
-
Sector Analysis
Parkinson's Disease in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which...
-
Sector Analysis
Parkinson’s Disease Epidemiology Analysis and Forecast to 2033
Parkinson’s Disease Report Overview In the 7MM, there were 2,636,930 diagnosed prevalent cases of Parkinson’s Disease in 2023. The market will register an AGR of more than 1% during 2023-2033. This increase in the cases of PD across the 7MM is primarily attributed to changes in the underlying population demographics. Parkinson’s disease (PD) is an incurable neurodegenerative disease clinically categorized as a movement disorder with prominent motor symptoms, including tremors, rigidity, and bradykinesia. The clinical presentation of PD is characterized...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.